Bristol, Roche team up on melanoma study Print E-mail
By BioMedReports.com Staff   
Thursday, 02 June 2011 19:49

Below is a look at some of the headlines for companies that made news in the healthcare sector on June 2, 2011.

Bristol-Myers Squibb (NYSE:BMY) and Roche Holding AG (OTC:RHHBY) said they would evaluate their cancer drugs as a potential combination therapy for metastatic melanoma.

The collaboration involves a Phase I/II study with Bristol's recently approved Yervoy and Roche's experimental drug, vemurafenib, to determine the safety and efficacy of the combination in treating the deadliest form of skin cancer.

Among the most eagerly anticipated studies being presented at the ASCO meeting will be a Phase III trial intended to show that vemurafenib extended the lives of patients with advanced melanoma, and another study comparing Yervoy to chemotherapy in patients with the fatal disease.

If proven effective and approved the Yervoy-vemurafenib combination would be an extremely expensive treatment option that could meet with reimbursement resistance from government programs and health insurers.

The collaboration with Bristol follows closely on the heels of Roche striking a deal with another large drugmaker, Merck & Co (NYSE:MRK), to co-promote hepatitis C medicines.


Also Thursday:

 
Adeona Pharmaceuticals, Inc. (NYSE Amex:AEN), a developer of innovative medicines for serious central nervous system diseases, announced today positive findings based on further analyses from the clinical study evaluating reaZin along with near-term plans for its Alzheimer's disease program.

Assisted Living Concepts, Inc. (NYSE: ALC) announced that it will present at the Jefferies 2011 Global Healthcare Conference on June 6, 2011 at the Grand Hyatt New York located at 109 East 42nd Street, Grand Central Terminal, New York, NY 10017.

Clovis Oncology, Inc. and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that they have entered into an agreement to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test.

Codexis, Inc. (Nasdaq:CDXS) today announced that Equilon Enterprises LLC, a wholly owned subsidiary of Royal Dutch Shell plc, has completed the transfer of approximately 5.6 million shares of Codexis common stock (which represents approximately 15.7% of Codexis' total outstanding shares) to Raizen Energia Participacoes S.A., a Brazil-based biofuels joint venture between Shell and Cosan Limited.  This transfer occurred as part of the closing of the joint venture.  

Cytori Therapeutics (NASDAQ: CYTX) has received Japanese Patent No. 4722041 (the '041 patent) covering the preparation of adipose-derived stem and regenerative cell (ADRC) enriched fat grafts using any closed system, such as Cytori's Celution® System.

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that it has acquired Neighborhood Diabetes, Inc., a leading durable medical equipment distributor specializing in direct to consumer sales of diabetes supplies, including pharmaceuticals, and support services, for total consideration of approximately $63 million in cash and stock.

Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, has demonstrated a pattern of strong preclinical efficacy in a variety of animal models of disease, including central nervous system (CNS) disorders, with Lpathomab™, a monoclonal antibody against lysophosphatidic acid (LPA).

Medco Health Solutions, Inc. (NYSE:MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients.

NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders, today announced that additional data from a 12-month open-label trial of its transdermal migraine patch (also referred to as Zelrix and NP101) and two other Zelrix trials will be presented at the 53rd Annual Scientific Meeting of the American Headache Society (AHS) this week in Washington, DC.

OPTIMIZERx Corporation (OTCBB: OPRX) announced today that North Coast Advisors ("NCA") has issued a research update regarding current business developments at OPTIMIZERx.

Phototron Holdings, Inc. (OTCQB: PHOT) (OTCBB: PHOT), the designer, manufacturer and seller of the PHOTOTRON Hydroponic Indoor Grow Systems, today announced that Brian Sagheb, Chief Financial Officer of Phototron, will also serve as interim Chief Financial Officer of GrowLife Inc., Phototron's wholly owned direct selling subsidiary.

Radient Pharmaceuticals Corporation (NYSE Amex: RPC) ("RPC" or "the Company"), a developer and global marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has filed an 8K with the Securities and Exchange Commission ("SEC") reporting it received an event of default notice from two of the note holders of private financings RPC completed between March 22, 2010 and April 26, 2010 ("2010 Debt Financing") pursuant to which such holders' notes shall become immediately due and payable.

Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it and its subsidiary Sequenom Center for Molecular Medicine® (Sequenom CMM) have secured a $30.0 million financing commitment from Silicon Valley Bank’s San Diego-based team.

Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it recently appointed Joseph Warusz as its new Vice President of Administration and Controller.

Spherix Incorporated (NASDAQ: SPEXD) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.

United Health Products, Inc. (OTCQB: UEEC) (PINKSHEETS: UEEC), which develops and markets products and technologies in the healthcare sector, today announced it has elected new members to its Board of Directors.

UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has hired Denny Mulloy to assume the role of Executive Vice President of Sales, Marketing and Alliances for UV Flu, and its wholly owned subsidiary, Rx Air.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter